Importer of Controlled Substances; Notice of Application, 45781 [E8-18055]
Download as PDF
<![CDATA[
45781
Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices
Springfield, Virginia 22152; and must be
filed no later than September 5, 2008.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–18045 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on June 5,
2008, Boehringer Ingelheim Chemicals,
Inc., 2820 N. Normandy Drive,
Petersburg, Virginia 23805, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance to bulk
manufacture amphetamine.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
VerDate Aug<31>2005
16:46 Aug 05, 2008
Jkt 214001
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA. 22152; and must be
filed no later than September 5, 2008.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–18055 Filed 8–5–08; 8:45 am]
manufacture of diagnostic products for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Roche Diagnostics Operations, Inc. to
import the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Roche Diagnostics
Operations, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and § 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–18064 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated March 10, 2008 and
published in the Federal Register on
March 19, 2008, (73 FR 14839), Roche
Diagnostics Operations, Inc., Attn:
Regulatory Compliance, 9115 Hague
Road, Indianapolis, Indiana 46250,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Schedule
Lysergic acid diethylamide (7315)
Alphamethadol (9605) ..................
Tetrahydrocannabinols (7370) .....
Cocaine (9041) .............................
Ecgonine (9180) ...........................
Methadone (9250) ........................
Morphine (9300) ...........................
I
I
I
II
II
II
II
The company plans to import the
listed controlled substances for the
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
Importer of Controlled Substances;
Notice of Registration
By Notice dated February 12, 2008
and published in the Federal Register
on February 21, 2008, (73 FR 9591),
United States Pharmacopeial
Convention, 12601 Twinbrook Parkway,
Rockville, Maryland 20852, made
application to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Cathinone (1235) ..........................
Methaqualone (2565) ....................
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) ......
4-Methyl-2,5dimethoxyamphetamine (7395).
3,4-Methylenedioxyamphetamine
(7400).
Codeine-n-oxide (9053) ................
Heroin (9200) ................................
Amphetamine (1100) ....................
E:\FR\FM\06AUN1.SGM
06AUN1
Schedule
I
I
I
I
I
I
I
I
I
II
]]>Agencies
[Federal Register Volume 73, Number 152 (Wednesday, August 6, 2008)]
[Notices]
[Page 45781]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-18055]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on June 5, 2008, Boehringer
Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia
23805, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as an importer of Phenylacetone
(8501), a basic class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance to bulk
manufacture amphetamine.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, VA. 22152; and must be filed no later
than September 5, 2008.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745), all applicants
for registration to import a basic class of any controlled substance in
schedule I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-18055 Filed 8-5-08; 8:45 am]
BILLING CODE 4410-09-P
